Merck’s Positive CETP Inhibitor Study Results Could Bode Well For Drug Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm has not made a final decision to move anacetrapib into Phase III trials, Merck tells "The Pink Sheet" DAILY.
You may also be interested in...
Merck's CETP Inhibitor Anacetrapib Will Enter Phase III In 2008, With Cardiovascular Outcomes Study To Follow
Company will go ahead with Phase III program after reviewing Phase III data on Pfizer's failed CETP inhibitor torcetrapib.
Merck's CETP Inhibitor Anacetrapib Will Enter Phase III In 2008, With Cardiovascular Outcomes Study To Follow
Company will go ahead with Phase III program after reviewing Phase III data on Pfizer's failed CETP inhibitor torcetrapib.
Pfizer’s Torcetrapib Shown Ineffective At Slowing Coronary Plaque Build-Up
Uncertainty remains as to whether failures are class related or specific to torcetrapib, lead investigator Nissen tells “The Pink Sheet” DAILY.